# About Clinic Retatrutide: An Editorial Reading Desk — Retatrutide Research Digest

> Clinic Retatrutide is an independent editorial publisher summarizing peer-reviewed research on Retatrutide. Not a clinic, not a vendor, not a medical practice.

## About This Reading Desk

Clinic Retatrutide is an independent editorial project that publishes summaries of the peer-reviewed research literature on Retatrutide — the investigational GLP-1/GIP/glucagon triple agonist developed by Eli Lilly and Company. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The 'clinic' in our name is editorial framing — a position this reading desk occupies relative to the clinical literature, not a claim about the site's services. We are a reading desk for the trial record, not a medical facility, not a vendor, and not a prescribing service. No consultation, treatment, or prescription service is offered or implied.

Our editorial scope: Phase 2 trials published in the New England Journal of Medicine and the Lancet (2023); Phase 2a liver disease data published in Nature Medicine (2024); Phase 3 TRIUMPH program topline results (2025); mechanism and structural biology studies from Cell Discovery and related journals (2024); pharmacokinetics and safety reviews from Clinical Diabetes, Biomolecules, and Current Cardiovascular Risk Reports (2024–2025); and meta-analyses from PMC and PubMed (2024–2025).

Every quantitative claim on this site is cited. We do not invent data. We do not recommend doses. We do not advise anyone to take any compound. We summarize what the clinical trial record has measured.

Retatrutide is an investigational compound. It is not FDA approved. It is not approved by any regulatory agency as of May 2026. It is accessible only through authorized Eli Lilly clinical trial enrollment. Nothing on this site changes that status or constitutes advice to seek out the compound outside authorized channels.

The [retatrutide mechanism of action](/research#mechanism), the [retatrutide dosage](/dosage) literature, and [retatrutide side effects](/side-effects) documented in the trial record are all described here in the language of research — 'studied at X mg/week in Phase 2,' not 'take X mg/day.' That distinction is the foundation of how we write.

---

A peer-reviewed reading desk — not a clinic, not a vendor, not a source of medical guidance.